Turkish Journal of Medical Sciences
Volume 37

Number 2

Article 5

1-1-2007

Development of a Highly Sensitive ELISA for Quantification of
Hepatitis B Virus (HBV) Surface Antigen (HBsAg)
RESUL KARAKUŞ
LATİFE ARZU ARAL
BİLKAY BAŞTÜRK
CEMALETTİN AYBAY

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
KARAKUŞ, RESUL; ARAL, LATİFE ARZU; BAŞTÜRK, BİLKAY; and AYBAY, CEMALETTİN (2007)
"Development of a Highly Sensitive ELISA for Quantification of Hepatitis B Virus (HBV) Surface Antigen
(HBsAg)," Turkish Journal of Medical Sciences: Vol. 37: No. 2, Article 5. Available at:
https://journals.tubitak.gov.tr/medical/vol37/iss2/5

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

ORIGINAL ARTICLE

Resul KARAKUﬁ
Latife Arzu ARAL
Bilkay BAﬁTÜRK
Cemalettin AYBAY

Turk J Med Sci
2007; 37 (2): 87-92
© TÜB‹TAK
E-mail: medsci@tubitak.gov.tr

Development of a Highly Sensitive ELISA for
Quantification of Hepatitis B Virus (HBV)
Surface Antigen (HBsAg)
Background: Hepatitis B Virus (HBV) infection is of global importance and many studies are aimed to develop
more sensitive diagnostic tools and improve therapeutic options. HBV infection is diagnosed and followed-up
basically by serological studies, among which the enzyme-linked immunosorbent assay (ELISA) is widely used.
Aim: To develop a sensitive HBsAg ELISA for both research and diagnostic purposes.
Materials and Methods: A hybridoma (clone 4D1) secreting anti-HBs IgG2a monoclonal antibody (mAb) was
used for the establishment of our in-house ELISA. Tests were performed for both cell culture medium and
human sera. The hepatoma cell lines of human origin PLC/PRF/5 and Hep G2 were used for validation assays.
®
Tests for human sera were run concurrently with the Access Immunoassay System.
Results: The in-house ELISA system had an analytical sensitivity less than 0.41 ng/ml for both human sera
®
and cell culture medium. The performance comparison of our in-house ELISA system with the Access
Immunoassay System even for samples with s/co levels of 1.5-13.7 gave a significant correlation.
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Conclusions: These reliable results of the newly established HBsAg ELISA system make it a promising
candidate for diagnostic as well as research purposes.
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Hepatit B Virus (HBV) Yüzey Antijeninin (HBsAg) Ölçümü Amac› ile
Yüksek Düzeyde Hassas Bir ELISA Kitinin Geliﬂtirilmesi
Giriﬂ ve Amaç: Hepatit B Virus (HBV) infeksiyonlar› dünya çap›nda büyük öneme sahiptir. Terapötik
seçeneklerin iyileﬂtirilmesi ve daha hassas tan› araçlar›n›n geliﬂtirilmesi için birçok araﬂt›rma yürütülmektedir.
Biz, bu çal›ﬂmam›zda gerek araﬂt›rma gerekse tan›sal amaçl› kullan›labilecek hassas bir HBV yüzey antijeni
(HBsAg) ELISA kiti geliﬂtirmeyi amaçlad›k.
Yöntem ve Gereç: ELISA kitinin geliﬂtirilmesi için immünglobulin G2a izotipinde monoklonal antikor salg›layan
bir hibridoma klonu (Klon 4D1) kullan›ld›. Testler hem hücre kültür besiyeri hem de insan serumu için
gerçekleﬂtirildi. ‹nsan kökenli PLC/PRF/5 ve Hep G2 hepatoma hücreleri kullan›larak geçerlilik çal›ﬂmas› yap›ld›.
®
‹nsan serumu için yap›lan testler ayn› zamanda “Access Immunoassay System” ile de çal›ﬂ›ld›.
Bulgular: Laboratuvar›m›zda oluﬂturdu¤umuz ELISA sistemi ile 0,41 ng/ml’den daha düﬂük bir analitik
sensitivite saptand›. Oluﬂturdu¤umuz ELISA sisteminin s/co düzeyleri 1,5-13,7 olan serumlar için yap›lan
performans karﬂ›laﬂt›rmas›nda önemli bir korrelasyon elde edildi.
Sonuç: Oluﬂturdu¤umuz ELISA sistemine dair elde edilen güvenilir sonuçlar, bu testin gerek tan›sal gerekse
araﬂt›rma amaçlar› için uygun olabildi¤ini göstermektedir.
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Introduction

Resul KARAKUﬁ

Hepatitis B Virus (HBV) infection is of global epidemiological concern, with about
350 million people chronically infected. The endemicity, which varies geographically, is
considered high when chronic infection prevalence is about 8%-15%. This means a high
cost for HBV infection related diseases and the main goal is prevention of transmission
and thus chronic liver diseases due to HBV infection. Vaccination remains the principal
means of prevention (1,2).
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In order to determine the infection status, various
serological markers like HBsAg, anti-HBs, and anti-HBc
are assessed. In the pre-nucleic acid testing era,
quantitation of HBsAg was found to be a significant tool
for predicting the outcome of an acute HBV infection (3).
Acute HBV infection patients who show a decrease in
HBsAg concentration by more than 50% in the first 3
weeks develop a clearance of HBsAg from the circulation
within 6 months, whereas patients who do not show such
a decrease become carriers (4). Newer generation, more
sensitive enzyme-linked immunosorbent assays (ELISAs)
have shortened the window period of HBV infection
course by several days in comparison to less sensitive
ELISAs. The availability of more sensitive HBsAg ELISAs
provides an important means for earlier detection of
blood donors who display the window period of HBV
infection and thus prevents transfusion related
transmissions. Nucleic acid testings show a greater
sensitivity in comparison to ELISAs in earlier detection of
HBV infection (5). However, the ease of availability and
increasing sensitivities of ELISAs make these methods
more affordable and applicable in comparison to
expensive and labor-intensive assays. The present study
aimed to develop an in-house ELISA system for the
quantification of HBsAg in human serum and in cell
culture medium.

Materials and Methods
Cell lines and monoclonal antibody purification
Previously established “a” epitope specific anti-HBsAg
monoclonal IgG2a secreting hybridoma clone 4D1 was
®
cultured in flasks (CellStar , Greiner Bio-one GmbH,
Germany) in RPMI-1640 (Biochrom, Berlin, Germany)
supplemented with 10% IgG-depleted FBS (FBS- Gold,
PAA Laboratories, Linz, Austria) (6). The culture
supernatant was precipitated with 50% (v/v) of saturated
®
ammonium sulfate overnight and dialyzed (Spectra/Por ,
12-14 kDa, Spectrum Medical, USA) against 10 mM, pH
7.4 phosphate buffered saline (PBS) overnight and
filtered (0.2 µm filter, Corning Incorporated, Corning,
Germany) afterwards. The filtrate was loaded onto a
Protein G column (Protein G-Agarose, 2 ml, Roche
Diagnostics GmbH, Mannheim, Germany) attached to a
high-pressure liquid chromatography system (1100
Series, Agilent Technologies, Waldbronn, Germany) and
IgG2a was eluted with 0.1 M citric acid, pH 2.4, and
88
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®
neutralized immediately with Trizma base (Tris
(hydroxymethyl) aminomethane, Sigma). The peak
fraction of the eluate was run through a 0.7 x 30 cm
Sephadex G-25 Fine column. Protein content of the
purified monoclonal antibody was determined using
bovine serum albumin (BSA) as the standard. Anti-HBs
®
value of the purified mAb was assessed by Access
Autoanalyzer.

In order to determine the performance of the
developed ELISA with cell culture medium, human
hepatocellular carcinoma derived cell line supernatants
were tested for their HBsAg content. For this purpose, a
hepatoma cell line known to secrete HBsAg, PLC/PRF/5
(ATCC® Number: CRL-8024™), and a hepatoma cell line
known not to secrete HBsAg, Hep G2 (ATCC® Number:
HB-8065™), were used. Cell lines were thawed and
cultured in RPMI-1640 supplemented with 10% FBS in
24-well cell culture plates. Supernatants were collected
when 70%-80% confluency was observed for each cell
line using an inverted microscope.

Human sera and antigen
Human sera used in this study were collected
randomly from residual sera sent to our laboratory for
diagnostic purposes. Each sample was tested for its
HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc (total)
content by Access® (Beckmann Instruments Inc., Access®
Immunoassay System, which will be referred to hereafter
as Access®) and classified according to their HBsAg
presence. All samples were stored at –80 °C until study.
“ad” and “ay” subtypes HBs antigens were commercially
obtained (Human plasma derived, purified, Biodesign,
Biodesign International, Saco, ME, USA).

Enzyme-Linked Immunosorbent Assay
The performance of the in-house HBsAg ELISA was
evaluated for cell culture medium (RPMI-1640,
supplemented with 10% FBS) and pooled human sera
(HBsAg negative as determined by Access®) separately.
High-binding capacity ELISA microtiter plates (Costar,
Corning Inc., USA) were coated with anti-HBs IgG2a at 2
µg/ml in 0.05 M carbonate-bicarbonate buffer (CBB), pH
9.6, 100 µl/well, by overnight incubation at +4 °C. Plates
were blocked with 1% BSA-PBS, 200 µl/well for 3 h at
RT and washed 3 times with PBS containing 0.05%
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Tween 20 (PBS-T). Standard antigen was prepared by
mixing equal amounts of “ad” and “ay” subtypes and was
serially diluted either in culture medium (RPMI-1640,
supplemented with 10% FBS) or human sera. Plates
were incubated for 1 h at RT and then washed (ELISA
Washer, Columbus Plus, Tecan, Austria) 3 times with
PBS-T. To each well was added 100 µl of biotinylated
anti-HBs IgG2a (clone 4D1 derived mAb) at a
concentration of 50 ng/ml, which was determined in
preliminary assays exploiting a checkerboard system.
After the plates were incubated for 1 h at RT, they were
washed 3 times with PBS-T. Streptavidin-horse radish
peroxidase was added (100 µl/well) and incubated for 30
min at RT and washed 3 times with PBS-T afterwards.
3,3’,5,5’ Tetramethylbenzidine (TMB) solution was added
(100 µl/well) and incubated for 30 min at RT and the
revealed reaction was stopped by adding 100 µl of 1 M
H2SO4 per well. Plates were read at 450/620 nm by an
ELISA reader (ELISA Reader, Sunrise, Tecan, Austria).
The minimum detection limit of ELISA was calculated
by adding 2 x SD to the mean optical density (OD)
obtained with HBsAg negative human sera. Thereafter, to
evaluate the performance characteristics of the in-house
ELISA, Access®-verified human sera were used. Human
serum samples were randomly selected from HBsAg
positive and HBsAg negative human sera assessed by
Access® for their antigen content. A total of 48 HBsAg
negative and 21 HBsAg positive human sera were studied
with the in-house ELISA for their HBsAg amount. Results
obtained by our in-house ELISA were analyzed for
correlation with the antigen levels measured by Access®.
Additionally, to test the cut-off value of the in-house
ELISA and to compare it with Access®, HBsAg antigens
(“ad”:“ay” = 1:1) diluted in Access® verified and pooled
HBsAg negative human sera were run concurrently with
both Access® and the in-house ELISA.
Statistical analyses
Regression-correlation analyses were performed and
inter- and intra-assay coefficients of variation (CV) were
calculated. SPSS for Windows, version 10.0, was used for
the statistical calculations.
Results
Analytical sensitivity of the in-house HBsAg ELISA
format was evaluated for cell culture medium and pooled
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human sera (HBsAg negative as determined by Access®)
separately. Hepatitis B virus surface antigens (“ad”:“ay” =
1:1) at various concentrations were prepared in either
culture medium or human sera and were run according to
the ELISA protocol described above. As depicted in Figure
1a and 1b, the models gave comparable results. The cutoff values of cell culture medium and human serum ELISA
formats were determined by adding 2 standard
deviations to the mean OD obtained when antigen
negative wells were assayed 4 times. This yielded a cutoff value of 0.091 and 0.085 for human sera and cell
culture medium ELISA formats, respectively. According to
these baseline data, the analytical sensitivity of the HBsAg
ELISA format for both human sera (mean OD = 0.1) and
cell culture medium (mean OD = 0.115) was less than
0.41 ng/ml.
Quality control of the in-house ELISA format was
evaluated by calculating its CVs for intra- and inter-assay
differences in ODs at certain concentrations of antigen.
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Figure 1. Enzyme-linked immunosorbent assay of HBsAg. Anti-HBs
monoclonal antibody- coated wells were incubated with
varying amounts of HBsAg subtypes “ad”, “ay” or mixed
(“ad”:“ay” = 1:1). Characteristics of the in-house ELISA
format for antigen subtypes and mixed content in cell
culture medium and human sera are shown. Figure 1a
depicts HBsAg (“ad”, “ay”, and “ad”:“ay” = 1:1) dilution in
2
cell culture medium (for mixed content, r = 0.994, P <
0.01) and Figure 1b depicts the dilution of the HBsAg in
pooled human sera (for mixed content, r2 = 0.999, P <
0.001). The overlapping ODs relevant to certain antigen
concentrations make symbols overlap especially for antigen
concentrations below 5 ng/ml. Results for both depictions
are the mean of quadruplicate observations.
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When the supernatants of the hepatoma cell lines
cultured in RPMI-1640 supplemented with 10% FBS
were evaluated by the in-house ELISA, it was observed
that the supernatants of PLC/PRF/5 had a prominent high
OD. On the other hand, supernatants of Hep G2 had an
OD equivalent to the cell culture medium without antigen.
Tested supernatants of the cell lines and their relevant
ODs are depicted in Figure 3.

ng/ml determined by in-house ELISA

In order to test defined concentrations of HBsAg in
human sera, HBsAg (“ad”:“ay” = 1:1) was diluted in
pooled human sera, which was predefined by Access® as
HBsAg negative. Samples were run concurrently with
Access® and the in-house ELISA. As shown in Figure 4,
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0
Figure 3. Human hepatoma cell lines PLC/PRF/5 and Hep G2 were
cultured in RPMI-1640 supplemented with 10% FBS and
supernatants were evaluated for HBsAg content. The mean
OD (450/620 nm) of PLC/PRF/5 (dark bar) was found to be
1.58 (equivalent to 24.4 ng/ml mixed antigen content, i.e.
“ad”+”ay”). Tested supernatants of Hep G2 cells (empty
bar) revealed a mean OD of 0.085, which was below the
detection limit of the in-house ELISA and similar to the ODs
of cell culture medium without antigen. Results are the
mean of quadruplicate observations.

the in-house ELISA could measure the lowest
concentration (0.41 ng/ml) that gave a s/co of 1.23 with
Access®. The antigen concentration of 0.14 ng/ml was
not detectable with Access® or the in-house ELISA.
Statistical correlation gave a coefficient of 0.99 (Pearson,
P < 0.001).
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Figure 2. HBsAg serum samples with s/co levels of 1.5-13.7, as
®
determined by Access , were assayed with the in-house
ELISA. As detailed in the results section, the in-house ELISA
correctly defined 13 out of 13 serum samples. A high
correlation coefficient was yielded between the assays
(Pearson correlation 0.91, two-tailed, P < 0.001).
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OD 450/620 nm

The HBsAg ELISA system developed for human sera
was also checked for its performance characteristics with
®
Access predefined human sera. Human sera defined as
HBsAg negative (n = 48) and HBsAg positive (n = 21,
among them 13 sera with s/co values of 1.5-13.7) by
Access® were assayed with the in-house ELISA format. All
of the 48 samples determined as negative by Access®
were also defined as negative with the in-house ELISA. It
was also the case for HBsAg positive human sera and all
samples were determined as positive by the in-house
ELISA. A high correlation coefficient (Pearson 0.91, P <
0.001) was yielded when the assays were compared for
s/co levels of 1.5-13.7, as shown in Figure 2.

1.8

OD 450/620 nm

This procedure was performed for both cell culture
medium and pooled human serum separately. As can be
seen in the Table in detail, favorable low variations below
10% were observed for both HBsAg ELISA formats.

Access Immunoassay s/co

KARAKUﬁ, R et al.

Figure 4. Comparison of HBsAg diluted to various concentrations in
®
human sera with both Access and in-house HBsAg ELISA.
®
HBsAg antigens (“ad”:“ay” = 1:1) were diluted in Access
verified and pooled HBsAg negative human sera and were
run concurrently with both Access® and in-house ELISA.
Solid line represents the s/co of one for Access® and dashed
line represents the cut-off value of the in-house ELISA
(0.091). The correlation coefficient was statistically
significant (Pearson correlation 0.99, 2-tailed, P < 0.001).
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Discussion
In order to define the infection status in HBV infected
individuals or to screen donors for potential HBV
infections, several markers are assayed by various
methods. Long before the onset of clinical symptoms,
HBsAg is one of the serum markers that can be detected
in the course of HBV infection. Either for screening or for
follow-up purposes, there are many HBsAg detection
systems commercially available and ELISAs are widely
used for these purposes (7,8). However, there is a
continuous challenge regarding the sensitivities of the
HBsAg detection systems. By using more sensitive assay
systems, low levels of HBsAg can be detected, so that the
residual risk of transfusion associated HBV infection can
be minimized and the window period can be further
reduced. Although there are more sensitive assays
available, such as nucleic acid amplification techniques,
their limitations make them difficult for wide-range use in
blood screening laboratories and thus easily applied
methods are being investigated (7). In addition, clinical
practices aimed to foresee the HBV infection course, not
just the presence but also the quantitation of HBsAg, may
also be an important tool in certain research areas (3,9).
Several cell lines that secrete HBsAg into the culture
medium are being exploited for various hypothesis
testing, including anti-viral research, and efficiency of
transfections by measuring HBsAg quantitatively (10,11).
The in-house HBsAg ELISA system we report in this
study has a sensitive level of measurement of HBsAg with
a significant correlation with regard to the validation tests
2
(for human sera, r = 0.999, P < 0.001; for cell culture
2
medium, r = 0.994, P < 0.01). Additionally, as detailed
in the Table, CVs of both human sera and cell culture
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medium formats were good reflections of assay precision
and reproducibility (12,13). In order to evaluate the
performance characteristics of our in-house ELISA
further, we assayed human sera defined by Access® as
HBsAg negative and HBsAg positive. The results obtained
were satisfactory, defining all negative and all positive
samples correctly. For sera samples with s/co levels of
1.5-13.7, our ELISA format gave a high correlation with
the established Access® (Pearson, 0.91, P < 0.001). We
also assayed 30 PCR verified HBV DNA positive human
sera reflecting a certain range of DNA copies/ml (data not
shown) and found no correlation with the amount of HBV
DNA and HBsAg titers, as also stated in the literature
(14). Our in-house HBsAg ELISA system also showed an
efficient performance with supernatant of PLC/PRF/5 and
Hep G2 cell lines cultured in RPMI-1640 supplemented
with 10% FBS. As expected, it measured HBsAg content
in the supernatants of PLC/PRF/5 cells but no antigen in
the supernatant of Hep G2 cells. When antigens at certain
concentrations (diluted in pooled, Access® predefined
HBsAg negative human sera) were tested for the
comparison of cut-off values, it was observed that the inhouse ELISA system was as good as Access®.
Concentrations lower than 0.41 ng/ml fell beyond the
cut-off values for both systems, and overall a very high
correlation (Pearson correlation 0.99, P < 0.001) was
observed.
In conclusion, the results of our in-house developed
HBsAg ELISA reflect a reliable and cost-effective
alternative for certain purposes. It has good sensitivity
for HBsAg detection and quantitation. It is promising for
investigational analysis of HBsAg even at low
concentrations in both human sera and cell culture
medium.

Table. Intra- and inter-assay coefficients of variation (CV) of the in-house HBsAg ELISA for cell culture medium and pooled human sera.
a
Antigen (ng/ml)

Cell culture medium

Human sera

a

Intra-assay CV% (n = 4)

Inter-assay CV% (n = 4)

33

2.1

1.6

11

1.3

2

3.7

1.2

2.6

1.2

0.8

1.2

33

0.6

1.1

11

2.2

1.6

3.7

4.9

4.5

1.2

6.8

5.5

Hepatitis B virus surface antigens “ad” and “ay” = 1:1
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